Claim Missing Document
Check
Articles

Found 3 Documents
Search

Serological Profiles of Systemic Lupus Erythematosus in Humanized Mice and Pristane-Induced Lupus Models Syahrul Chilmi; Dimas Ikhsan Airlangga; Hani Susianti; Kusworini Handono
Folia Medica Indonesiana Vol. 60 No. 2 (2024): June
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/fmi.v60i2.56828

Abstract

Highlights:1. This study compared the serological markers of pristane-induced mice to humanized mouse models of lupus achieved by transplanting stem cells from lupus patients, which is a novel method in Indonesia.2. This study will allow for more accurate research into the pathophysiology of the disease and the development of new lupus treatment strategies.   Abstract More studies related to systemic lupus erythematosus (SLE) therapy are urgently needed because of the current insufficiency in treatment effectiveness. However, due to ethical limitations, researchers use experimental animals as a substitute for conducting studies on humans. Models commonly used to study lupus include the pristane-induced mouse model and the recently developed humanized mouse model. The second model involves implanting human immune cells into immunodeficient mice. This study compared the serologic profiles of lupus antibodies, the antinuclear antibodies (ANA) and anti-double stranded DNA (anti-dsDNA), in both mouse models. The aim was to determine which one is more promising for use as a lupus animal model. Thirty BALB/c mice (Mus musculus) were used as subjects and divided into three groups: K1, K2, and K3. K1 served as the control group, consisting of healthy mice that received a placebo. The K2 mice were intraperitoneally injected with 0.5 cc of pristane. The K3 mice were transplanted with stem cell cultures from SLE patients, resulting in humanized mice with immune deficiencies. The mice were observed for 16 weeks, during which the ANA and anti-dsDNA levels in their serum were obtained for analysis using the Kruskal-Wallis test (p<0.05). The comparison revealed differences in the average ANA and anti-dsDNA levels among the three groups. K3 had the highest ANA and anti-dsDNA levels, followed by K1 and K2. The Kruskal-Wallis test indicated that the differences were not significant in the mean levels of ANA (p=0.156) and anti-dsDNA (p=0.061). In conclusion, the humanized mouse model has higher ANA and anti-dsDNA antibody levels compared to the pristane-induced mouse model, albeit without a significant difference. This suggests a positive picture of the humanized mouse model of lupus, making it an invaluable tool for studying the disease and testing potential therapeutic interventions.  
Association of clinical manifestations, disease activity, and medications on premature atherosclerosis in systemic lupus erythematosus Pratama, Mirza Zaka; Kusworini Handono; Cesarius Singgih Wahono; Ahmad Bayhaqi Nasir Aslam; Syahrul Chilmi
Heart Science Journal Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2025.006.01.11

Abstract

Background SLE is distinguished by the development of multiple autoantibodies that lead to chronic inflammation and increased risk of cardiovascular diseases, especially atherosclerosis. Objective This examination sought to explore the association between the disease activity, clinical manifestations, and medication with the atherosclerotic lesion from SLE patients. Methods This inquiry investigated forty-two female SLE patients (18-45 years old) who met the 2019 EULAR/ACR assortment decency with matched healthy individuals as control A cross-sectional study was sanctioned at the Rheumatology Clinic of Saiful Anwar General Hospital Malang between July and November 2023. Demographic data, clinical manifestations, and medication history was documented in the medical records. Disease activity was stelled by the SLEDAI-2K score. Carotid Intima-Media Thickness (cIMT) and Flow-Mediated Dilation (FMD) (after brachial BP cuff inflation up to 200 mmHg for five minutes) examinations were used as atherosclerosis marker. Results Markedly higher of cIMT mean was demonstrated in SLE patients compared to healthy individual (0.51±0.11 vs 0.40±0.11 mm, p<0.001). FMD was subtancially curtailed in SLE patients set side to side to control (0.00 (0.00-0.10) vs 0.10 (0.00-0.28) mm, p=0.022). There was no statistical distinctness of the cIMT and FMD among SLE patients according to the presence of clinical manifestations. Neither cIMT nor FMD showed a statistically correlated with the disease activity. Patients who received hydroxychloroquine (0.57±0.02 vs. 0.50±0.09 mm, p=0.043) and cyclophosphamide (0.55±0.09 vs. 0.48 ± 0.10 mm, p=0.031) had higher cIMT. Higher cIMT was demonstrated in subjects who received steroid (p=0.045) and the dosage of steroid was essentially enforced to cIMT (R=0.418, p=0.034). Conclusion Our study unveil that early atherosclerosis was evidenced in patients with SLE and several medications might affect the progressivity of atherosclerosis.
Association of clinical manifestations, disease activity, and medications on premature atherosclerosis in systemic lupus erythematosus Pratama, Mirza Zaka; Kusworini Handono; Cesarius Singgih Wahono; Ahmad Bayhaqi Nasir Aslam; Syahrul Chilmi
Heart Science Journal Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2025.006.01.11

Abstract

Background SLE is distinguished by the development of multiple autoantibodies that lead to chronic inflammation and increased risk of cardiovascular diseases, especially atherosclerosis. Objective This examination sought to explore the association between the disease activity, clinical manifestations, and medication with the atherosclerotic lesion from SLE patients. Methods This inquiry investigated forty-two female SLE patients (18-45 years old) who met the 2019 EULAR/ACR assortment decency with matched healthy individuals as control A cross-sectional study was sanctioned at the Rheumatology Clinic of Saiful Anwar General Hospital Malang between July and November 2023. Demographic data, clinical manifestations, and medication history was documented in the medical records. Disease activity was stelled by the SLEDAI-2K score. Carotid Intima-Media Thickness (cIMT) and Flow-Mediated Dilation (FMD) (after brachial BP cuff inflation up to 200 mmHg for five minutes) examinations were used as atherosclerosis marker. Results Markedly higher of cIMT mean was demonstrated in SLE patients compared to healthy individual (0.51±0.11 vs 0.40±0.11 mm, p<0.001). FMD was subtancially curtailed in SLE patients set side to side to control (0.00 (0.00-0.10) vs 0.10 (0.00-0.28) mm, p=0.022). There was no statistical distinctness of the cIMT and FMD among SLE patients according to the presence of clinical manifestations. Neither cIMT nor FMD showed a statistically correlated with the disease activity. Patients who received hydroxychloroquine (0.57±0.02 vs. 0.50±0.09 mm, p=0.043) and cyclophosphamide (0.55±0.09 vs. 0.48 ± 0.10 mm, p=0.031) had higher cIMT. Higher cIMT was demonstrated in subjects who received steroid (p=0.045) and the dosage of steroid was essentially enforced to cIMT (R=0.418, p=0.034). Conclusion Our study unveil that early atherosclerosis was evidenced in patients with SLE and several medications might affect the progressivity of atherosclerosis.